Conference Coverage
Conference Coverage
‘Baby TAM’ effective, tolerable for breast cancer prevention
A new study shows that a lower dose of tamoxifen leads to better adherence, and another shows similar efficacy at reducing breast density.
Conference Coverage
Women over 50 may safely de-escalate mammogram frequency following surgery
For women who were cancer free 3 years after curative treatment, a randomized trial showed noninferiority of a 2- or 3-year schedule compared with...
Conference Coverage
Sickle Cell Gene Therapy ‘Truly Transformative’
New research on a just-approved gene therapy for sickle cell disease shows the efficacy of a single infusion of lovo-cel.
Conference Coverage
CAR T-Cell Therapy: Cure for Systemic Autoimmune Diseases?
New research suggests that CAR T-cell therapy might prove to be a game-changing treatment for lupus and two other autoimmune diseases.
Conference Coverage
In real world, patients with myeloma have worse outcomes
Canadian study indicates that real-world outcomes for patients treated for myeloma fall far short of those in clinical trials.
Conference Coverage
Compelling case for skipping RT in some early breast cancers
Results of the PROSPECT study have defined a role for preoperative MRI in identifying a subgroup of women with early breast cancer who could...
Conference Coverage
FDA’s Project Optimus aims to transform early cancer research
Q & A with an expert on how the FDA’s Project Optimus targets toxicity and how it could spell the end of traditional dose-escalation trials....
Conference Coverage
In MI with anemia, results may favor liberal transfusion: MINT
This study is “not a home run,” for the primary outcome, however, many of the outcomes tended to be in favor of a liberal transfusion strategy.
Conference Coverage
Particulate pollution increases the risk for breast cancer
“There is now strong epidemiological and biological evidence for the link between PM2.5 particulate exposure and cancer ...”
Conference Coverage
T-cell cancers: CAR T therapy to the rescue?
Trials are small and incomplete, but CAR T-cell therapy has yielded promising early results in treating T-cell blood cancers.
